Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M549Revenue $M9.8Net Margin (%)-1,391.7Z-Score3.3
Enterprise Value $M344EPS $-3.4Operating Margin %-1,371.2F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-1,391.7Higher ROA y-yY
Price/Book2.310-y EBITDA Growth Rate %-4.9Quick Ratio6.7Cash flow > EarningsY
Price/Sales54.55-y EBITDA Growth Rate %28.7Current Ratio6.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-44.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-51.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M41.3ROI % (ttm)-300.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 13.28-27%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 13.28-69%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 13.28-138%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 13.28-91%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 13.28-123%Reduce -64.98%233,000
SRPTAndreas Halvorsen 2013-09-30 Sold Out -0.14%$30.906 - $47.97
($38.37)
$ 13.28-189%Sold Out0
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 13.28-189%Add 56.28%665,274
SRPTAndreas Halvorsen 2013-03-31 Buy 0.15%$23.97 - $36.95
($28.83)
$ 13.28-117%New holding690,731
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 13.28-117%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 13.28-101%Add 184.13%226,429
SRPTJean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6
($6.06)
$ 13.2854%Sold Out0
SRPTJean-Marie Eveillard 2011-12-31 Reduce$3.24 - $6.54
($5.04)
$ 13.2862%Reduce -83.33%50,000
SRPTJean-Marie Eveillard 2011-09-30 Add$6.3 - $9.9
($7.92)
$ 13.2840%Add 50.00%300,000
SRPTJean-Marie Eveillard 2011-06-30 Buy $8.1 - $11.22
($9.66)
$ 13.2827%New holding200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.828.97view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.828.97view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95-7.67view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.562.55view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-65.23view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-63.17view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-60.59view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-58.59view
Price Ben GilDirector 2013-08-19Buy500$31.18-58.69view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-66.55view

Press Releases about SRPT :

    Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 

    More From Other Websites
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 24 2015
    Sarepta Therapeutics' 3 Biggest Risks Mar 23 2015
    Amicus Up As FDA, EU Green-light Quick Drug Filings Mar 19 2015
    This Upcoming Event Could Affect Sarepta Therapeutics Investors Mar 18 2015
    FDA panel to discuss Ebola vaccine development in May Mar 18 2015
    FDA panel to discuss Ebola vaccine development in May Mar 18 2015
    Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog Mar 17 2015
    Should We Be Concerned For Sarepta’s Share Prices? Mar 02 2015
    ZMapp Ebola Trial Starts In Liberia: Is It Too Late? Mar 01 2015
    U.S., Liberia kick off trial of Ebola drug ZMapp Feb 27 2015
    Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today Feb 26 2015
    Sarepta Therapeutics reports 4Q loss Feb 26 2015
    Sarepta Therapeutics reports 4Q loss Feb 26 2015
    SAREPTA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Feb 26 2015
    SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 26 2015
    Q4 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open Feb 26 2015
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent... Feb 26 2015
    Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog Feb 24 2015
    Medicago wins contract to develop Ebola treatments Feb 24 2015
    Medicago wins contract to develop Ebola treatments Feb 24 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK